Bone and Cancer
Bone and Cancer
Bone and CancerBone and Cancer Foundation, PO Box 287452 Bone and Cancer New York, NY 10128-0025  
Toll Free: 888 862-0999 Bone and Cancer Email: bcfdn@aol.com  
Bone and Cancer

Clinical Trials

Mobic (meloxicam) Tablets

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Approval Status:

Approved April 2000

Specific Treatments:

For relief of the signs and symptoms of osteoarthritis

General Information

Mobic is a once-daily, 7.5 mg tablet indicated for the relief of the pain and stiffness associated with osteoarthritis. Mobic is a non-steroidal anti-inflammatory drug (NSAID).

Osteoarthritis is a disease which affects approximately 80% of Americans over the age of 65. The disease, which causes the cartilage in the joints to break down, is especially painful and debilitating.

Clinical Results

A double-blind, controlled study was conducted in the U.S. to evaluate the safety and efficacy of Mobic. The 12-week study involved 464 patients who had osteoarthritis of the knee and hip. When three different doses of Mobic (3.5 mg, 7.5 mg, and 15 mg daily) were compared to placebo, results indicated that both the 7.5 and 15 mg daily doses of Mobic significantly decreased symptoms of pain, function, and stiffness in patients, with a low incidence of gastrointestinal side effects.

Six similar studies were conducted outside of the U.S. Results were consistent with those found in the U.S. study.

Side Effects

Although Mobic tablets are generally well-tolerated gastrointestinally, gastrointestinal ulcers may develop without warning symptoms. While taking Mobic, specific attention should be paid to any sign of gastrointestinal bleeding.

Do not use Mobic if:

  • you have a known allergy to meloxicam, aspirin or other NSAIDs
  • you are, or may be, pregnant

Mechanism of Action

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic activities in models. The mechanism of action of meloxicam, like that of other NSAIDs, may be related to prostaglandin synthetase (cyclooxygenase) inhibition.
(From FDA Label)

Additional Information

Mobic, which will be marketed jointly in the U.S. by Boehringer Ingelheim Pharmaceuticals, Inc. and Abbott Laboratories, will be priced approximately 20% less than some other osteoarthritis drugs in its class.

Visit the Boehringer Ingelheim Pharmaceuticals, Inc. web site to learn more about Mobic and about other products, research, and services provided by the company that developed this drug.

For more information about osteoarthritis and research and treatments in this field, visit the web site of the Arthritis Foundation: www.arthritis.org

 How To Order Publications:
  Glossary
  FAQ

Information About

Clinical Trials



 

 

 

 

 

 

 

 

 

 

 


 

 

 

 

 

 

 


  Copyright 2011 - The Bone and Cancer Foundation